Evaluation of the Efficacy and Safety of a Paclitaxel Eluting PTCA Balloon Catheter in Coronary In-stent Restenosis

Coronary In-stent Restenosis Clinical Trial

Official title:

Evaluation of the Efficacy and Safety of a Paclitaxel Eluting PTCA Balloon Catheter in Coronary In-stent Restenosis: a Randomized, Open-label, Positive Parallel Controlled, Multicenter Clinical Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04213378
• Other study ID #: SAHZJU CT016
• Status: Recruiting
• Phase: Phase 2/Phase 3
• Start date: January 1, 2017
• Est. completion date: December 31, 2020

Study information

• Verified date: December 2019
• Source: Second Affiliated Hospital, School of Medicine, Zhejiang University
• Contact: Jun Jiang, MD, PhD
• Phone: +86-13588706891
• Email: 2106002[@]zju.edu.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Over the past two decades, stents implantation has developed as a standard treatment for coronary stenosis lesions. However, int-stent restenosis (ISR) was one of the main factors affecting the long-term efficacy of coronary artery interventional therapy, with the incidence of ISR after percutaneous coronary intervention ranging from 5% to 35%. At present, there are three main means for ISR: (1) simple balloon dilation; 2) intravascular radiotherapy; and (3) drug elution stent. But the results are still not ideal. Drug coated balloon (DCB) is a new method that may be used to treat ISR in recent years. In the PEPCAD II study, when dealing with ISR, the paclitaxel eluting balloon (PEB) SeQuent® Please significantly reduced the major adverse cardiovascular events (MACEs) compared to the paclitaxel eluting stent (PES) TAXUS Liberte. In ISR-I and ISR-II trial, it was found that compared with uncoated PTCA balloons, PEB could significantly inhibit endothelial hyperplasia and significantly reduce MACEs treating ISR. The purpose of this study was to assess the efficacy and safety of a Chinese-developed PEB in treatment of coronary ISR compared to SeQuent® Please PEB.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 212
• Est. completion date: December 31, 2020
• Est. primary completion date: January 31, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Patients oriented

1. Patients with age between 18 and 80 years old (including 18 and 80 years old);

2. Patients with stable angina, or unstable angina pectoris, or old myocardial infarction (MI) or with evidence of local myocardial ischemia although without symptoms;

3. Patients with restenosis after the first time stent implantation of de novo coronary lesions (i.e., no other surgical treatments for the target lesions except for the first stent implantation);

4. Patients with the willing to receive their own coronary angioplasty;

5. Patients with LVEF>30% measured within 30 days before recruitment;

6. Patients agree to receive 9-month angiography follow-up, and agree to receive 30 days, 6 months, 12 months clinical follow-up;

7. Patients at the age of childbirth must take effective contraception measures until the study is completed since they are chosen into screening period;

8. Patients agree to take part in the trial and sign the informed consent.

• Lesions oriented (Visual estimation)

1. Patients with Mehran type I, type II and type III in-stent restenosis (ISR);

2. Reference vascular diameter between 2.0-4.0 mm (including 2.0 and 4.0 mm), length<30mm;

3. The percent of lumen ISR =70%, or =50% with local ischemia evidence before interventional surgery;

4. Patients with residual stenosis =30%, and = type B dissection post pretreatment;

5. Distance between other lesions that require treatment and target lesions >10 mm;

6. Patients with coronary artery anatomy allowing delivery of research device to target lesions.

Exclusion Criteria:

• Patients oriented

1. Subjects with consistent clinical symptoms and/or ECG changes and/or cardiac enzymes changes with MI (including STEMI and Non-STEMI) within one week;

2. Subjects with cardiac shock, hemodynamic instability or refractory ventricular arrhythmia that require positive inotropic drugs or mechanical circulation support;

3. Subjects with one of following conditions (from screening period to the day of operation): (1) life expectancy is less than 1 year because of other severe diseases (like cancer), (2) drug abuse at present (like alcohol, cocaine, heroin and so on), (3) plan to accept surgery that may cause the programs not to be complied with or confusing with data understanding;

4. Subjects with bleeding diathesis or active gastrointestinal ulcers, or stroke/transient ischemic attack within 3 months;

5. Subjects with severe congestive heart failure or severe heart failure at the level of NYHA IV;

6. Subjects are receiving dialysis or baseline serum creatinine levels>2.0 mg/dL(177µmol/L);

7. Subjects with severe valvular heart disease;

8. Subjects who have been or are scheduled for a heart transplantation during the trial;

9. Subjects who have been pregnant or is planning to be pregnant or is breastfeeding during the trial;

10. Subjects who are participating in any other clinical trial;

11. Researchers don't think they're suitable for the trial because of other reasons;

• Lesions oriented (Visual estimation)

1. Total occlusion with TIMI 0 (Mehran IV stenosis);

2. With the evidence of widespread thrombi in the target vessels prior to intervention;

3. Planning to treat >3 lesions (i.e., up to 3 target lesions);

4. Planning to treat >2 major epicardial vessels (i.e., up to 2 target lesions);

5. Planning to treat a single lesions with more than 1 balloon;

6. Planning to treat a true bifurcation lesion with double stents technique;

7. Left main lesions.

• Combined medication oriented

1. Subjects known to intolerant to dual antiplatelet therapy for 3 months post interventional treatment (e.g., aspirin and/or ticagrelor and/or clopidogrel);

2. Subjects with leukopenia (WBC<3x10^9/L for more than 3 days) or neutropenia (NEUT<1x10^9/L for more than 3 days) or a history of platelet reduction (PLT 30x10^9/L);

3. Subjects known to be intolerant or allergic to paclitaxel.

Related Conditions & MeSH terms

• Coronary In-stent Restenosis

Intervention

Device:
• Paclitaxel eluting PTCA balloon
Treatment of coronary in-stent re-stenosis with paclitaxel eluting PTCA balloon
• SeQuent® Please paclitaxel eluting balloon
Treatment of coronary in-stent re-stenosis with SeQuent® Please paclitaxel eluting balloon

Locations

Country	Name	City	State
China	Second Affiliated Hospital, School of Medicine, Zhejiang University	Hangzhou	Zhejiang

Sponsors (14)

Lead Sponsor

Collaborator

Second Affiliated Hospital, School of Medicine, Zhejiang University

First Affiliated Hospital of Wenzhou Medical University, Hainan People's Hospital, Hebei Medical University Third Hospital, Renmin Hospital of Wuhan University, Second Affiliated Hospital of Wenzhou Medical University, Shanghai Chest Hospital, Taizhou Hospital, TEDA International Cardiovascular Hospital, The First Affiliated Hospital of Xiamen University, The Second Hospital of Shandong University, The Third Xiangya Hospital of Central South University, Tianjin People's Hospital, West China Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate of target lesion late lumen loss		9 months
Secondary	Rate of interventional therapy success	Including rate of device success, rate of disease success and rate of clinical success	0-24 hours, 30 days, 6 months, 9 months, 12 months
Secondary	Rate of target lesion restenosis		9 months
Secondary	Device-oriented composite clinical cardiovascular outcomes	Cardiac death, target vessel-related myocardial infarction, symptoms-driven target lesion revascularization	30 days, 6 months, 9 months, 12 months
Secondary	Patient-oriented composite clinical cardiovascular outcomes	All-cause mortality, all myocardial infarction, all revascularization	30 days, 6 months, 9 months, 12 months
Secondary	Rate of ARC defined thrombosis events	All definite, probable and possible thrombosis in acute, subacute and late stage	0-24 hours, 30 days, 6 months, 9 months, 12 months